According to intraoperative metabolomic analysis, tumor core site 1 was identified as IDH wildtype glioma with a confidence level of 0.999, while edema region sites 2 to 5 were identified as non-tumor tissue with confidence levels of 0.785, 0.810, 0.898, and 0.915, respectively. The gene discussed is IDH2; the disease is central nervous system cancer.